| Similar Articles |
|---|
 |
Bio-IT World
April 2007
Vicki Glaser |
Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics.   |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
The Motley Fool
March 27, 2008
Brian Lawler |
A Little Bit of Cash for ArQule Development-stage drugmaker ArQule announces that it has received a milestone payment for discovery-stage drug work that it performed for partner Wyeth. |
Chemistry World
January 2012 |
Rising interest in compound bank David Fox argues for the creation of a centralized repository for small molecules to harness research efforts in drug discovery |
The Motley Fool
July 20, 2005
Karl Thiel |
Pride and Preclinicals Biotech ArQule has surged, but take its early-stage data with a grain of salt. |
The Motley Fool
April 5, 2004
Charly Travers |
A Biotech's Transition to Drugs A deal with Roche gives ArQule's drug program a leg up. ArQule has spent the last year transitioning from a services company into a drug developer. Last week's deal with Roche could signify that the transition is complete. |
The Motley Fool
August 13, 2007
Andrew R. Vaino |
Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow. |
